Tenecteplase or Alteplase Better in Patients with Acute Ischemic Stroke Due to Large Vessel Occlusion: A Single Center Observational Study

特奈特普酶 医学 溶栓 纤溶剂 优势比 组织纤溶酶原激活剂 冲程(发动机) 单中心 瑞替普酶 内科学 心脏病学 外科 麻醉 心肌梗塞 机械工程 工程类
作者
Agnete Teivane,Kristaps Jurjāns,Jānis Vētra,Jekaterina Grigorjeva,Karlis Kupcs,Rytis Masiliūnas,Evija Miglāne
出处
期刊:Medicina-lithuania [MDPI AG]
卷期号:58 (9): 1169-1169
标识
DOI:10.3390/medicina58091169
摘要

Background and Objectives: The study aimed to investigate the efficacy of intravenous thrombolysis with Tenecteplase before thrombectomy for acute ischemic stroke (AIS) patients compared with previous results using Alteplase. Previous trials for Tenecteplase have indicated an increased incidence of vascular reperfusion. In April 2021, we started to primarily give Tenecteplase to patients eligible to undergo thrombectomy. Materials and Methods: In this retrospective observational single-center non-randomized study, we analyzed directly admitted patients with AIS who had occlusion of the internal carotid, middle cerebral, or basilar artery and who underwent thrombectomy, as well as the recanalization rate for these patients at the first angiographic assessment (mTICI score 2b-3), and complications. Results: We included 184 patients (demographic characteristics did not differ between Tenecteplase and Alteplase groups (mean age 68.4 vs. 73.0 years; female sex 53.3% vs. 51.1%, NIHSS 14 (IQR 4-26) vs. 15 (2-31). Forty-five patients received Tenecteplase and 139 Alteplase before endovascular treatment (EVT). Pre-EVT (endovascular treatment) recanalization was more likely to occur with Tenecteplase rather than Alteplase (22.2% vs. 8.6%, p = 0.02). Successful reperfusion (mTICI 2b-3) after EVT was achieved in 155 patients (42 (93.4%) vs. 113 (81.3), p = 0.07). Hemorrhagic imbibition occurred in 15 (33.3%) Tenecteplase-treated patients compared with 39 (28.1%) Alteplase-treated patients (p = 0.5). Patients treated with Tenecteplase had higher odds of excellent functional outcome than Alteplase-treated patients (Tenecteplase 48.6% vs. Alteplase 26.1%; OR 0.37 (95% CI 0.17-0.81), p = 0.01). Conclusions: Tenecteplase (25 mg/kg) could have superior clinical efficacy over Alteplase for AIS patients with large-vessel occlusion (LVO), administered before EVT. The improvement in reperfusion rate and the better excellent functional outcome could come without an increased safety concern.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
笨笨的银耳汤完成签到,获得积分10
刚刚
3秒前
MewZero发布了新的文献求助10
3秒前
4秒前
小马甲应助卡拉米人采纳,获得10
4秒前
友好从灵发布了新的文献求助10
5秒前
6秒前
乐乐应助^O^采纳,获得10
6秒前
www发布了新的文献求助10
7秒前
000完成签到,获得积分10
8秒前
8秒前
8秒前
干净的琦应助暴躁的灭绝采纳,获得10
8秒前
Judy发布了新的文献求助10
9秒前
000关闭了000文献求助
9秒前
斗战圣牛完成签到,获得积分10
10秒前
墨橙完成签到,获得积分10
12秒前
12秒前
14秒前
15秒前
16秒前
yyyyyxy完成签到,获得积分10
16秒前
深情安青应助limbo采纳,获得10
17秒前
友好从灵完成签到,获得积分10
17秒前
Jasper应助木木采纳,获得10
19秒前
pluto应助shsf采纳,获得10
19秒前
19秒前
王WW完成签到,获得积分10
20秒前
11发布了新的文献求助10
20秒前
ljq完成签到,获得积分10
21秒前
ys716发布了新的文献求助10
22秒前
缥缈千风完成签到,获得积分10
23秒前
aaqaq123321完成签到,获得积分10
23秒前
23秒前
再也不拖发布了新的文献求助10
25秒前
搜集达人应助Judy采纳,获得10
25秒前
嘿嘿发布了新的文献求助10
27秒前
勤恳的元绿完成签到,获得积分10
28秒前
顾矜应助灰二采纳,获得10
28秒前
浪子发布了新的文献求助10
29秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Modern Epidemiology, Fourth Edition 5000
Kinesiophobia : a new view of chronic pain behavior 5000
Molecular Biology of Cancer: Mechanisms, Targets, and Therapeutics 3000
Digital Twins of Advanced Materials Processing 2000
Weaponeering, Fourth Edition – Two Volume SET 2000
Signals, Systems, and Signal Processing 610
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 纳米技术 化学工程 生物化学 物理 计算机科学 内科学 复合材料 催化作用 物理化学 光电子学 电极 冶金 细胞生物学 基因
热门帖子
关注 科研通微信公众号,转发送积分 6018383
求助须知:如何正确求助?哪些是违规求助? 7606838
关于积分的说明 16159054
捐赠科研通 5166032
什么是DOI,文献DOI怎么找? 2765153
邀请新用户注册赠送积分活动 1746686
关于科研通互助平台的介绍 1635339